More DailyStrength
Health Event Calendar
See what's new on the site
Step-by-step Tutorials
How to use DailyStrength
We're on Facebook
Check out our page
Follow us on Twitter
Read our tweets
Get Cool DS Stuff!!!!!
Shirts, Hats, Baby Wear

Chronic Myelogenous Leukemia (CML) Information

  • Chronic myelogenous leukemia (or CML) is a form of chronic leukemia characterized by increased production of myeloid cells in the bone marrow. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. It is traditionally treated with chemotherapy, interferon and bone marrow transplantation, although a specific inhibitor (imatinib mesylate) has radically changed the management...
  • Patients are often asymptomatic at diagnosis, presenting incidentally with an elevated white blood count on a routine laboratory test. Symptoms may include: malaise, low grade fever, increased susceptibility to infections, anemia and thrombocytopenia with resultant bruising (although an increased platelet count, thrombocytosis, may be a feature). Splenomegaly may also be seen.

    The disease may remain dormant for years, but a proportion proceed to accelerated phase (in which the disease progresses rapidly) or transform to overt blast crisis, which may have the symptoms and risks of acute myelogenous leukemia (AML) or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL), depending on the hematopoietic lineage that is involved in the transformation.

    Chronic phase CML is treated with Imatinib (marketed as Gleevec or Glivec; previously known as STI-571). In the past, hydroxyurea, alkylating agents (e.g. cytarabine), interferon alfa 2b and steroids were used, but this has been replaced by Imatinib. Imatinib is a new agent approved by the US FDA in 2001 which specifically targets the abnormality caused by the Philadelphia chromosome. It is better tolerated and more effective than previous therapies. Bone marrow transplants were also used as initial treatment for CML before Imatinib and can be curative.

    A new Drug, dasatinib (marketed as Sprycel; previously known as BMS-354825) was approved by the US FDA in June 2006 for use in patients with CML who are no longer responding to, or who can no longer tolerate, therapy with imatinib. [1]

    Various combinations of the different treatment modalities are being explored. In 2005, Bocchia et al reported favourable results of vaccination with the bcr-abl p210 fusion protein in patients with stable disease, with GM-CSF as an adjuvant. Two other drugs, ceflatonin (homoharringtonine) and AMN 107 (nilotinib) are currently in active clinical trials in patients with Chronic Myeloid Leukemia (CML) who have developed resistance to Imatinib.

    Blast crisis carries all the symptoms and characteristics of either acute myelogenous leukemia or acute lymphoblastic leukemia, and has a very high mortality rate. This stage can most effectively be treated by a bone marrow transplant after high-dose chemotherapy. In young patients in the accelerated phase, a transplant may also be an option. However the likelihood of relapse after a bone marrow transplant is higher in patients in blast crisis or in the accelerated phase as compared to patients in the chronic phase.

  • Click to expand

Health Blogs

Cancer is one of the most fear inducing words in our culture; and it is the number one disease American’s wish to avoid, according to on-line surveys. While cancer research has yet to find the magic bullet for knocking out cancer, there is good news about this deadly disease. As far back as November of 1996, Harvard School of Public Health ... Read More »
Most of what we have learned about pain in the last few years has helped answer why patients with some pain syndromes, have pain. Fibromyalgia, irritable bowel syndrome, interstitial cystitis, TMJ, chronic low back pain, and tension headaches have associated pain that is difficult to treat with traditional medications. Specific options for ... Read More »
Guidelines have recently changed regarding this vaccine, so it is good to know if you need a shingles vaccine, or not. The shingles vaccine, Zostavax, is indicated for people age 50 and older to prevent zoster (shingles.) Shingles is a painful blistering skin condition that results because of reactivation of the chicken pox virus. The shingles ... Read More »

Member Photos


Latest Activity